Molecule
Emtricitabine is a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is available as capsules and oral solution. MedsAcross supplies Emtricitabine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EMTRIVA ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. EMTRIVA, a nucleoside analog HIV-1 reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Source: US FDA prescribing information
Emtricitabine is an antiretroviral drug.
Source: US FDA prescribing information
Testing: Prior to or when initiating EMTRIVA test for hepatitis B virus infection. EMTRIVA may be taken without regard to food. Adult Patients (18 years of age and older): EMTRIVA capsules: One 200 mg capsule administered once daily orally. EMTRIVA oral solution: 240 mg (24 mL) administered once daily orally. Pediatric Patients (0–3 months of age): EMTRIVA oral solution: 3 mg/kg administered once daily orally. Pediatric Patients (3 months through 17 years of age): EMTRIVA capsules: For children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally. EMTRIVA oral solution: 6 mg/kg up to a maximum of 240 mg (24 mL) administered once daily orally.
Source: US FDA prescribing information
EMTRIVA is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products.
Source: US FDA prescribing information
Boxed warning (posttreatment acute exacerbation of hepatitis b): Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue EMTRIVA. Immune reconstitution syndrome: May necessitate further evaluation and treatment. Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.
Source: US FDA prescribing information
The following adverse reactions are discussed in other sections of the labeling: Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV. Immune Reconstitution Syndrome. Lactic Acidosis/Severe Hepatomegaly with Steatosis. Most common adverse reactions (incidence ≥10%) are headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis. Skin hyperpigmentation was very common (≥10%) in pediatric patients.
Source: US FDA prescribing information
The potential for drug interactions with EMTRIVA has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). There were no clinically significant drug interactions for any of these drugs. Drug interactions trials are described elsewhere in the labeling.
Source: US FDA prescribing information
Store EMTRIVA oral solution refrigerated at 2–8 °C (36–46 °F). EMTRIVA oral solution should be used within 3 months if stored by the patient at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Emtricitabine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Emtricitabine 200 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Emtriva 10 mg/mL oral solutionOral Cold chain | Gilead Sciences | US FDA | Available on request |
| Emtriva 200 mg capsuleOral Cold chain | Gilead Sciences | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 3 presentations of Emtricitabine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Emtricitabine, including Emtriva.
Yes. The US FDA first approved Emtricitabine on 2 July 2003, according to Drugs@FDA.
Yes. Emtricitabine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Emtricitabine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Emtricitabine is classified under ATC code J05AF09 (Emtricitabine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.